177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Therapeutic Efficiency and Response to 177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Peking Union Medical College Hospital
10 participants
Sep 1, 2024
INTERVENTIONAL
Conditions
Summary
Researchers has conducted extensive research on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI, and some researches have revealed 68Ga-TATE-RGD in imaging studies of neuroendocrine tumors to find that the dual-targeted tracer showed an increasing TBR, suggesting the tracer kinetic advantage of TATE-RGD; compared to the single-target tracer DOTATATE, the dual-target TATE-RGD probe has a clear advantage in detecting liver metastases of NETs, and it can be explored for potential therapeutic uses of TATE-RGD in future studies and used for related companion diagnostics in targeted radioisotope therapy (RLT).
Eligibility
Inclusion Criteria3
- patients with clear pathological diagnosis and ineffective or progressing clinical conventional treatment;
- tumor lesions with high SSTR2 and RGD untake confirmed on 68Ga-TATE-RGD PET/CT within one week before the injection of 177Lu-TATE-RGD;
- signed written consent.
Exclusion Criteria1
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
accepted intravenous injection of 177Lu-TATE-RGD
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06632873